Global COVID-19 Vaccination Inequality: More Than 50 Countries Miss WHO's 10% Target

More Than 50 Countries Fall Behind the Global Vaccination Target

More than 50 countries around the world have failed to meet the World Health Organization's (WHO) target of fully vaccinating at least 10% of their populations against COVID-19 by the end of September. This situation highlights the significant inequalities in global vaccine distribution and the challenges faced by countries with limited access to vaccine supplies and healthcare resources.

The vaccination gap has been particularly pronounced across Africa, where only 4.4% of the population was fully vaccinated at the time. In comparison, vaccination coverage was considerably higher in several wealthier regions. In the United Kingdom, nearly 66% of the total population had received full vaccination, while the European Union had reached approximately 62%. In the United States, the proportion stood at around 55%.

These differences demonstrate how access to vaccines, healthcare infrastructure, purchasing capacity, and international distribution mechanisms have influenced the progress of national vaccination campaigns.

Which Countries Have Not Reached the WHO's 10% Vaccination Target?

Many countries that failed to achieve the 10% vaccination target were low-income nations facing significant difficulties in obtaining sufficient vaccine doses. However, economic limitations were not the only factor affecting vaccination progress. Political instability, armed conflicts, civil unrest, natural disasters, and logistical challenges also created substantial obstacles to implementing vaccination programmes.

Countries such as Yemen, Syria, Iraq, Afghanistan, and Myanmar experienced additional difficulties due to conflict and political instability. These circumstances affected healthcare infrastructure, disrupted medical services, and made the transportation and distribution of vaccines more complicated.

Haiti also faced considerable challenges following natural disasters, which placed additional pressure on an already vulnerable healthcare system and complicated vaccination efforts.

Interestingly, some countries with stronger economic resources also struggled to achieve the WHO target. Taiwan, for example, remained slightly below the 10% threshold, partly because its vaccination programme experienced delivery delays and other logistical difficulties.

Vietnam, which had previously reported some of the lowest coronavirus case numbers globally, also fell short of the vaccination target as the pandemic situation evolved and demand for vaccines increased.

Vaccination Progress Across Africa

Africa experienced particularly significant difficulties in achieving the WHO's vaccination objectives. Out of 54 countries on the continent, only 15 had reached the 10% target. Furthermore, approximately half of African countries had fully vaccinated less than 2% of their populations.

Several countries with large populations remained considerably below the target. Egypt had fully vaccinated approximately 5% of its population, while Ethiopia and Nigeria had each vaccinated less than 3%.

The situation was even more concerning in Burundi and Eritrea, which had not yet launched their national COVID-19 vaccination programmes at the time.

These figures illustrate the considerable differences in vaccination coverage across the African continent and emphasize the need for stronger international cooperation, improved vaccine availability, and more effective distribution strategies.

What Has Caused Global COVID-19 Vaccine Shortages?

One of the major factors contributing to vaccine shortages was the limited supply available through the COVID-19 Vaccines Global Access initiative, commonly known as COVAX.

COVAX was established to improve equitable access to COVID-19 vaccines, particularly for low- and middle-income countries that could not compete with wealthier nations in securing large quantities of doses directly from manufacturers.

However, the programme faced significant supply challenges. One of its main difficulties was its dependence on vaccines produced by the Serum Institute of India, the world's largest vaccine manufacturer.

In April, India suspended vaccine exports to prioritize its own urgent domestic vaccination requirements as COVID-19 infections increased across the country. This decision significantly affected the supply of vaccines available to COVAX and disrupted planned deliveries to several African countries.

At the same time, other vaccine manufacturers encountered difficulties increasing production capacity quickly enough to meet growing global demand.

The Impact of Vaccine Purchasing Agreements

Another important factor behind the unequal distribution of COVID-19 vaccines was the purchasing strategy adopted by wealthier countries.

Several high-income nations had already signed agreements with pharmaceutical manufacturers as early as July 2020, while many vaccine candidates were still under development and undergoing clinical trials.

These advance purchasing agreements allowed wealthier countries to secure substantial quantities of prospective vaccines before their widespread availability.

As a result, manufacturers frequently prioritized existing contractual commitments, making it more difficult for COVAX, the African Union, and individual developing countries to obtain sufficient vaccine doses.

This situation contributed to an imbalance in global vaccine distribution, leaving many countries dependent on international donation programmes and delayed deliveries.

COVAX Revises Its Vaccine Supply Forecasts

Earlier in September, COVAX released a statement regarding its projected vaccine supplies for the remainder of the year and the beginning of 2022. The initiative announced a reduction in the estimated number of doses it expected to receive.

Several factors contributed to this revision, including export restrictions, difficulties increasing manufacturing capacity, and delays in obtaining regulatory approval for certain vaccines.

India subsequently announced plans to resume some vaccine exports from October, with a particular focus on Asian countries and the COVAX initiative. However, the quantities that would become available remained uncertain.

The timing and remaining shelf life of donated vaccines also emerged as important concerns. Ayoade Alakija, of the African Union Vaccine Delivery Alliance, emphasized the importance of receiving doses with longer shelf lives when countries share their vaccine supplies.

This is particularly relevant because vaccine donations delivered close to their expiration dates can create additional logistical and administrative difficulties for countries that need sufficient time to organize vaccination campaigns.

Calls for International Vaccine Solidarity

The unequal distribution of vaccines also prompted calls for urgent international action.

Former UK Prime Minister Gordon Brown called for measures to ensure that millions of unused COVID-19 vaccine doses stored in wealthy countries would not go to waste.

His appeal highlighted the importance of redistributing surplus vaccine supplies to countries experiencing shortages, particularly those with limited purchasing power and healthcare resources.

International vaccine sharing was considered an important mechanism for improving access, preventing unnecessary wastage, and accelerating vaccination coverage in countries that remained significantly behind global targets.

How Many COVID-19 Vaccine Doses Does Africa Need?

The World Health Organization established an ambitious objective of fully vaccinating 40% of the global population by the end of 2021. Achieving this target required a substantial increase in vaccine production, international distribution, and national vaccination capacity.

However, Africa faced a considerable gap between the number of doses required and the quantities expected to become available through international distribution programmes.

COVAX had already revised its projected vaccine deliveries to Africa by the end of 2021, reducing its initial estimate from 620 million doses to approximately 470 million.

According to the projections at the time, this quantity would be sufficient to fully vaccinate only around 17% of Africa's population, leaving the continent considerably below the WHO's 40% vaccination objective.

An additional approximately 500 million doses would therefore be required for African countries to reach the target of fully vaccinating 40% of their populations by the end of December.

These estimates demonstrated the scale of the vaccination challenge facing African nations and the importance of increasing international vaccine supplies.

Challenges to Achieving the 40% Vaccination Target

Reaching the 40% vaccination target required more than simply securing additional doses. Countries also needed adequate healthcare infrastructure, trained medical personnel, reliable transportation systems, appropriate storage facilities, and effective vaccination campaigns.

The distribution of vaccines across geographically diverse populations presented additional challenges, particularly in rural and remote areas where access to healthcare services could be limited.

Furthermore, vaccination programmes needed to coordinate vaccine deliveries with national immunization strategies to ensure that available doses could be administered before their expiration dates.

Without improvements in vaccine supply and distribution, achieving the WHO's global vaccination objectives within the established deadlines remained difficult.

Africa's COVID-19 Vaccination Outlook

The slow pace of vaccination across Africa raised concerns about the continent's ability to achieve international immunization targets within the planned timeframe.

According to Dr. Matshidiso Moeti, WHO Regional Director for Africa, the continent was progressing too slowly to meet the 40% target by the end of December 2021.

She warned that, at the prevailing vaccination rate, Africa might not reach the 40% coverage objective until the end of March 2022.

This projection highlighted the urgent need for stronger international cooperation, increased vaccine production, more equitable distribution, and timely delivery of vaccine supplies.

The Importance of Equitable Global Vaccine Distribution

The difficulties experienced by more than 50 countries in achieving the WHO's 10% vaccination target revealed the significant inequalities affecting the global COVID-19 response.

While several high-income countries had achieved relatively high vaccination coverage, many developing nations continued to face shortages caused by limited manufacturing capacity, export restrictions, advance purchasing agreements, and logistical barriers.

The experience of African countries demonstrated that access to vaccines is closely linked to international cooperation and the availability of effective distribution mechanisms.

Achieving global vaccination objectives required coordinated efforts from governments, pharmaceutical manufacturers, international health organizations, and vaccine-sharing initiatives such as COVAX.

Ensuring equitable access to COVID-19 vaccines remained essential to supporting national vaccination programmes and strengthening the global response to the pandemic.